Generic Product News

Marketed by: Heritage Pharmaceuticals Inc

Compare to: Procardia (Pfizer, Inc)

Indication: Heritage Pharmaceuticals Inc announces the immediate availability of nifedipine soft gel capsules, an AB-rated generic equivalent of Pfizer Inc’s Procardia. It is indicated for the treatment of vasospastic angina and chronic stable angina, high blood pressure, and abnormal heart rhythms. The recommended dose is 1 capsule 3 times a day, with 10 mg as the recommended starting dose. Patients should be advised against taking the medicine with grapefruit juice.

Dosage Form: Soft gel capsules: 10 and 20 mg

For More Information: www.heritagepharma.com

Paricalcitol Capsules

Marketed by: Teva Pharmaceutical Industries Ltd

Compare to: Zemplar (AbbVie Inc)

Indication: Teva Pharmaceutical Industries Ltd announces the launch of paricalcitol capsules, the generic equivalent of Zemplar tablets in the United States. Paricalcitol capsules are an active form of vitamin D used to treat and prevent secondary hyperparathyroidism in patients with stage 3 or stage 4 chronic kidney disease and in stage 5 patients on dialysis. Information on dosage and administration can be found in the full prescribing information.

Dosage Form: Capsules: 1, 2, and 4 mcg

For More Information: www.tevagenerics.com

Acamprosate Calcium Delayed-Release Tablets

Marketed by: InnoPharma Inc and Glenmark Pharmaceuticals Inc

Compare to: Campral Delayed Release Tablets (Forest Laboratories)

Indication: InnoPharma Inc announces the launch of acamprosate calcium delayed-release tablets, a generic equivalent of Forest Laboratories’ Campral delayed-release tablets. InnoPharma has developed the generic formulation of acamprosate calcium delayed-release tablets and entered into an agreement with Glenmark Pharmaceuticals Inc, pursuant to which Glenmark will sell, market, and distribute acamprosate in the United States.

Dosage Form: Tablets: 333 mg

For More Information: www.innopharmainc.com; http://us.glenmark-generics.com

Azacitidine for Injection

Marketed by: Sandoz

Compare to: VIDAZA (Celgene Corporation)

Indication: Sandoz has launched azacitidine for injection, an authorized generic version of Celgene’s VIDAZA. It is indicated for the treatment of myelodysplastic syndrome, a bone disease formerly known as pre-leukemia, including refractory anemia, refractory anemia with ringed sideroblasts if accompanied by neutropenia or thrombocytopenia or requiring transfusions, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia. The recommended starting dose for the first treatment cycle is azacitidine for injection 75 mg/m² for 7 days to be administered subcutaneously or intravenously.

Dosage Form: Injection: 100-mg single-use vials

For More Information: http://www.us.sandoz.com/